FIELD: pharmaceutics.
SUBSTANCE: invention relates to new compounds of the formula (I), to pharmaceutical compositions containing these compounds, and to the use of these compounds in treatment of diseases mediated by FGFR activity, for example, cancer.
(I).
EFFECT: effective treatment of diseases mediated by FGFR activity.
20 cl, 3 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIGETEROARYL-SUBSTITUTED 1,4-BENZODIAZEPINES AND WAYS OF THEIR USE FOR CANCER TREATMENT | 2016 |
|
RU2747644C2 |
| PTERIDINES AS FGFR INHIBITORS | 2013 |
|
RU2702906C2 |
| QUINAZOLINONE DERIVATIVES APPLICABLE AS MODULATORS OF FGFR KINASE | 2014 |
|
RU2701517C2 |
| COMBINATION OF INHIBITOR FGFR AND INHIBITOR IGF1R | 2015 |
|
RU2715893C2 |
| SUBSTITUTED QUINAZINE DERIVATIVES AS FGFR-KINASE INHIBITORS FOR TREATMENT OF CANCER | 2011 |
|
RU2602233C2 |
| NEW COMPOUNDS | 2013 |
|
RU2654857C2 |
| COMBINATIONS | 2015 |
|
RU2715236C2 |
| COMPOUNDS BASED ON PYRAZOLOPYRIDINONE | 2018 |
|
RU2806625C2 |
| DERIVATIVES OF 1,5- AND 1,7-NAPHTHYRIDINE USEFUL IN TREATMENT OF FGFR-MEDIATED DISEASES | 2012 |
|
RU2629194C2 |
| NEW QUINOLINE COMPOUNDS | 2018 |
|
RU2810113C2 |
